Nektar reported Phase II extension results for rezpegaldesleukin (rezpeg) in severe alopecia areata, describing additional hair regrowth in patients continuing treatment. The update focused on late responders during a 16-week extension of the Phase II REZOLVE-AA study, supporting ongoing planning for future development steps. Separately, reporting around the rezpeg program has highlighted a growing narrative that response may continue to deepen with longer exposure, strengthening the case for further evaluation in broader or later-stage settings. With alopecia areata treatments increasingly competitive, the extension data add incremental clinical context that can influence trial design and partner discussions.